Product Images Metformin Hydrochloride

The table shows mean changes from baseline in Hemoglobin Ay, Fasting Plasma Glucose, and Body Weight over a period of 12 weeks and 24 weeks study. The changes are shown for patients on Metformin Hydrochloride tablets of 500mg, 1000mg, and 1500mg taken different times a day. The baseline and change at final visit are also indicated, along with the 95% CI.*

This text presents a summary of mean percent changes in the major serum lipid variables on participants in 29-week studies comparing different treatments. The lipid variables include total cholesterol, total triglycerides, LDL-cholesterol, and HDL-cholesterol. The study compares the effects of Metformin Hydrochloride Tablets vs. placebo, and combined Metformin Hydrochloride Tablets/Glyburide vs. monotherapy. The analysis is presented using a table.*

This text provides information on a study involving pediatric patients with a mean age of 13.8 years (ranging from 10 to 16 years) who were all undergoing diet therapy at baseline. The asterisk notation indicates that all patients were on therapy at the start of the study, and the double asterisk indicates that there was no statistically significant difference observed.*

This is a summary comparison of the effects of Metformin Hydrochloride Tablets versus placebo on fasting plasma glucose, HbA1c, and body weight after a 29-week study. The table presents the mean changes from baseline for 145 patients taking Metformin Hydrochloride Tablets and 141 patients taking placebo. Hemoglobin A1c and body weight showed statistically significant improvement with the medication while fasting plasma glucose did not. All patients were on diet therapy at baseline.*

Table 10 shows a summary of mean changes from baseline in plasma glucose and body weight at the final visit for Metformin Hydrochloride Tablets compared to Placebo in a pediatric population. The table displays results for FPG (mg/dL) and body weight (Ibs) at baseline and change at the final visit for both treatments. Metformin Hydrochloride Tablets showed a significant reduction in FPG and an increase in body weight compared to Placebo, as evidenced by the p-value. However, no significant difference was observed in body weight change between the two treatments.*

This is a table presenting the comparison of combined Metformin Hydrochloride Tablets and Insulin vs Placebo Insulin for the treatment of Hemoglobin A1c levels and daily insulin dose. The table shows the mean changes from baseline to final visit in 28 patients who received the Metformin Hydrochloride Tablets/ Insulin combination and 26 patients who received Placebo Insulin. The table also shows that there is a statistically significant treatment difference in Hemoglobin A1c levels between the two groups, but no significant difference in daily insulin dose.*